Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jul 30;138(1):146–159. doi: 10.1002/ijc.29682

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Line plots of individual changes in markers (matched data) across T1 (pretreatment) and T2, T3 and T4 (6 week, 6 month and at progression on fulvestrant respectively) for each patient. Wilcoxon Paired Signed‐Rank test compared staining between time‐points using paired sample data from each patient. Significance between T1‐T2, T1‐T3, T2‐T3, T1‐T4 or T3‐T4 is indicated by , , , and , respectively. To aid visualisation of profile over the multiple time‐points in these plots, marker data have been connected in the same patient if any sample was unavailable. (a) ER H Score (T1‐T2, T1‐T3, T2‐T3 falls p < 0.001; T1‐T4 fall p = 0.001); (b) PR H Score (T1‐T3 p < 0.001, T2‐T3 falls p = 0.006; T1‐T4 fall p = 0.012); (c) Bcl‐2% positivity (T1‐T3 fall p = 0.007; T3‐T4 increase p = 0.066); (d) pER (serine 118 phosphorylation) H Score; (e) HER2m (membrane) and HER2c (cytoplasmic) H Scores; (f) pHER2m (membrane) and pHER2c (cytoplasmic) H Scores (NB. no measurable staining was detected in any sample from 20 patients for HER2c and 16 patients for pHER2c); (g) EGFRm (membrane) and EGFRc (cytoplasmic) H Scores; (h) pEGFRm (membrane; T1‐T3 fall p = 0.024; T3‐T4 increase p = 0.012) and pEGFRc H Scores (cytoplasmic; T3‐T4 increase p = 0.041); (i) pMAPK H Score (T1‐T3 fall p = 0.019); (j) Ki67% positivity (T1‐T2 p = 0.001, T1‐T3 p = 0.012, T2‐T3 falls p = 0.048; T1‐T4 fall p = 0.028); (k) Tumour cellularity % (T1‐T2 fall p = 0.019; T1‐T3 fall p = 0.003; T3‐T4 increase p = 0.065).

Inline graphic — Line plots of individual changes in markers (matched data) across T1 (pretreatment) and T2, T3 and T4 (6 week, 6 month and at progression on fulvestrant respectively) for each patient. Wilcoxon Paired Signed‐Rank test compared staining between time‐points using paired sample data from each patient. Significance between T1‐T2, T1‐T3, T2‐T3, T1‐T4 or T3‐T4 is indicated by , , , and , respectively. To aid visualisation of profile over the multiple time‐points in these plots, marker data have been connected in the same patient if any sample was unavailable. (a) ER H Score (T1‐T2, T1‐T3, T2‐T3 falls p < 0.001; T1‐T4 fall p = 0.001); (b) PR H Score (T1‐T3 p < 0.001, T2‐T3 falls p = 0.006; T1‐T4 fall p = 0.012); (c) Bcl‐2% positivity (T1‐T3 fall p = 0.007; T3‐T4 increase p = 0.066); (d) pER (serine 118 phosphorylation) H Score; (e) HER2m (membrane) and HER2c (cytoplasmic) H Scores; (f) pHER2m (membrane) and pHER2c (cytoplasmic) H Scores (NB. no measurable staining was detected in any sample from 20 patients for HER2c and 16 patients for pHER2c); (g) EGFRm (membrane) and EGFRc (cytoplasmic) H Scores; (h) pEGFRm (membrane; T1‐T3 fall p = 0.024; T3‐T4 increase p = 0.012) and pEGFRc H Scores (cytoplasmic; T3‐T4 increase p = 0.041); (i) pMAPK H Score (T1‐T3 fall p = 0.019); (j) Ki67% positivity (T1‐T2 p = 0.001, T1‐T3 p = 0.012, T2‐T3 falls p = 0.048; T1‐T4 fall p = 0.028); (k) Tumour cellularity % (T1‐T2 fall p = 0.019; T1‐T3 fall p = 0.003; T3‐T4 increase p = 0.065).